Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation

A randomized clinical trial

Alan Cheng, Saman Nazarian, Jeffrey A. Brinker, Christine Tompkins, David D. Spragg, Charles T. Leng, Henry Halperin, Harikrishna Tandri, Sunil K. Sinha, Joseph E. Marine, Hugh Calkins, Gordon F. Tomaselli, Ronald D. Berger, Charles A. Henrikson

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: Management of oral anticoagulation in patients undergoing pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) implantation remains controversial. Prior studies demonstrate that continuation of warfarin may be safer when compared with strategies requiring interruption and/or heparin bridging. Limited data from randomized trials exist. Objective: We conducted a randomized trial to determine whether warfarin continuation is superior to warfarin interruption during PPM or ICD implantation. Methods: Patients on oral anticoagulation referred for PPM or ICD implantation were randomized to warfarin continuation versus interruption. Patients randomized to warfarin interruption were further stratified into two groups based on their risk for thromboembolic events in the absence of warfarin. Moderate-risk patients were randomized to warfarin continuation versus warfarin interruption. High-risk patients were randomized to warfarin continuation versus warfarin interruption with heparin bridging. The primary combined outcome included thromboembolic events, anticoagulant-related complications, or any significant bleeding necessitating additional intervention or discontinuation of anticoagulation. Results: We studied 100 patients (average age 70.8 years, 21% female, mean body mass index 28.4) who underwent 64 ICD and 36 PPM implantations. Fifty patients were assigned to continue warfarin. The randomized groups were well matched. Among patients randomized to warfarin interruption, there were two pocket hematomas, one pericardial effusion, one transient ischemic attack, and one patient who developed heparin-induced thrombocytopenia. No events were noted among patients continuing warfarin (P = .056). Conclusions: While the results were not statistically significant, there was a trend toward reduced complications in patients randomized to warfarin continuation. This strategy should be considered in patients undergoing PPM or ICD implantation.

Original languageEnglish (US)
Pages (from-to)536-540
Number of pages5
JournalHeart Rhythm
Volume8
Issue number4
DOIs
StatePublished - Apr 1 2011
Externally publishedYes

Fingerprint

Implantable Defibrillators
Warfarin
Randomized Controlled Trials
Heparin
Pericardial Effusion
Transient Ischemic Attack
Thrombocytopenia
Hematoma
Anticoagulants

Keywords

  • Anticoagulation
  • Bleeding
  • Heparin
  • ICD
  • Pacemaker
  • Stroke
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Cheng, A., Nazarian, S., Brinker, J. A., Tompkins, C., Spragg, D. D., Leng, C. T., ... Henrikson, C. A. (2011). Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: A randomized clinical trial. Heart Rhythm, 8(4), 536-540. https://doi.org/10.1016/j.hrthm.2010.12.016

Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation : A randomized clinical trial. / Cheng, Alan; Nazarian, Saman; Brinker, Jeffrey A.; Tompkins, Christine; Spragg, David D.; Leng, Charles T.; Halperin, Henry; Tandri, Harikrishna; Sinha, Sunil K.; Marine, Joseph E.; Calkins, Hugh; Tomaselli, Gordon F.; Berger, Ronald D.; Henrikson, Charles A.

In: Heart Rhythm, Vol. 8, No. 4, 01.04.2011, p. 536-540.

Research output: Contribution to journalArticle

Cheng, A, Nazarian, S, Brinker, JA, Tompkins, C, Spragg, DD, Leng, CT, Halperin, H, Tandri, H, Sinha, SK, Marine, JE, Calkins, H, Tomaselli, GF, Berger, RD & Henrikson, CA 2011, 'Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: A randomized clinical trial', Heart Rhythm, vol. 8, no. 4, pp. 536-540. https://doi.org/10.1016/j.hrthm.2010.12.016
Cheng, Alan ; Nazarian, Saman ; Brinker, Jeffrey A. ; Tompkins, Christine ; Spragg, David D. ; Leng, Charles T. ; Halperin, Henry ; Tandri, Harikrishna ; Sinha, Sunil K. ; Marine, Joseph E. ; Calkins, Hugh ; Tomaselli, Gordon F. ; Berger, Ronald D. ; Henrikson, Charles A. / Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation : A randomized clinical trial. In: Heart Rhythm. 2011 ; Vol. 8, No. 4. pp. 536-540.
@article{5bd13aab9bbd439aa020e8dd0aecbc1d,
title = "Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: A randomized clinical trial",
abstract = "Background: Management of oral anticoagulation in patients undergoing pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) implantation remains controversial. Prior studies demonstrate that continuation of warfarin may be safer when compared with strategies requiring interruption and/or heparin bridging. Limited data from randomized trials exist. Objective: We conducted a randomized trial to determine whether warfarin continuation is superior to warfarin interruption during PPM or ICD implantation. Methods: Patients on oral anticoagulation referred for PPM or ICD implantation were randomized to warfarin continuation versus interruption. Patients randomized to warfarin interruption were further stratified into two groups based on their risk for thromboembolic events in the absence of warfarin. Moderate-risk patients were randomized to warfarin continuation versus warfarin interruption. High-risk patients were randomized to warfarin continuation versus warfarin interruption with heparin bridging. The primary combined outcome included thromboembolic events, anticoagulant-related complications, or any significant bleeding necessitating additional intervention or discontinuation of anticoagulation. Results: We studied 100 patients (average age 70.8 years, 21{\%} female, mean body mass index 28.4) who underwent 64 ICD and 36 PPM implantations. Fifty patients were assigned to continue warfarin. The randomized groups were well matched. Among patients randomized to warfarin interruption, there were two pocket hematomas, one pericardial effusion, one transient ischemic attack, and one patient who developed heparin-induced thrombocytopenia. No events were noted among patients continuing warfarin (P = .056). Conclusions: While the results were not statistically significant, there was a trend toward reduced complications in patients randomized to warfarin continuation. This strategy should be considered in patients undergoing PPM or ICD implantation.",
keywords = "Anticoagulation, Bleeding, Heparin, ICD, Pacemaker, Stroke, Warfarin",
author = "Alan Cheng and Saman Nazarian and Brinker, {Jeffrey A.} and Christine Tompkins and Spragg, {David D.} and Leng, {Charles T.} and Henry Halperin and Harikrishna Tandri and Sinha, {Sunil K.} and Marine, {Joseph E.} and Hugh Calkins and Tomaselli, {Gordon F.} and Berger, {Ronald D.} and Henrikson, {Charles A.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.hrthm.2010.12.016",
language = "English (US)",
volume = "8",
pages = "536--540",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation

T2 - A randomized clinical trial

AU - Cheng, Alan

AU - Nazarian, Saman

AU - Brinker, Jeffrey A.

AU - Tompkins, Christine

AU - Spragg, David D.

AU - Leng, Charles T.

AU - Halperin, Henry

AU - Tandri, Harikrishna

AU - Sinha, Sunil K.

AU - Marine, Joseph E.

AU - Calkins, Hugh

AU - Tomaselli, Gordon F.

AU - Berger, Ronald D.

AU - Henrikson, Charles A.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Management of oral anticoagulation in patients undergoing pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) implantation remains controversial. Prior studies demonstrate that continuation of warfarin may be safer when compared with strategies requiring interruption and/or heparin bridging. Limited data from randomized trials exist. Objective: We conducted a randomized trial to determine whether warfarin continuation is superior to warfarin interruption during PPM or ICD implantation. Methods: Patients on oral anticoagulation referred for PPM or ICD implantation were randomized to warfarin continuation versus interruption. Patients randomized to warfarin interruption were further stratified into two groups based on their risk for thromboembolic events in the absence of warfarin. Moderate-risk patients were randomized to warfarin continuation versus warfarin interruption. High-risk patients were randomized to warfarin continuation versus warfarin interruption with heparin bridging. The primary combined outcome included thromboembolic events, anticoagulant-related complications, or any significant bleeding necessitating additional intervention or discontinuation of anticoagulation. Results: We studied 100 patients (average age 70.8 years, 21% female, mean body mass index 28.4) who underwent 64 ICD and 36 PPM implantations. Fifty patients were assigned to continue warfarin. The randomized groups were well matched. Among patients randomized to warfarin interruption, there were two pocket hematomas, one pericardial effusion, one transient ischemic attack, and one patient who developed heparin-induced thrombocytopenia. No events were noted among patients continuing warfarin (P = .056). Conclusions: While the results were not statistically significant, there was a trend toward reduced complications in patients randomized to warfarin continuation. This strategy should be considered in patients undergoing PPM or ICD implantation.

AB - Background: Management of oral anticoagulation in patients undergoing pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) implantation remains controversial. Prior studies demonstrate that continuation of warfarin may be safer when compared with strategies requiring interruption and/or heparin bridging. Limited data from randomized trials exist. Objective: We conducted a randomized trial to determine whether warfarin continuation is superior to warfarin interruption during PPM or ICD implantation. Methods: Patients on oral anticoagulation referred for PPM or ICD implantation were randomized to warfarin continuation versus interruption. Patients randomized to warfarin interruption were further stratified into two groups based on their risk for thromboembolic events in the absence of warfarin. Moderate-risk patients were randomized to warfarin continuation versus warfarin interruption. High-risk patients were randomized to warfarin continuation versus warfarin interruption with heparin bridging. The primary combined outcome included thromboembolic events, anticoagulant-related complications, or any significant bleeding necessitating additional intervention or discontinuation of anticoagulation. Results: We studied 100 patients (average age 70.8 years, 21% female, mean body mass index 28.4) who underwent 64 ICD and 36 PPM implantations. Fifty patients were assigned to continue warfarin. The randomized groups were well matched. Among patients randomized to warfarin interruption, there were two pocket hematomas, one pericardial effusion, one transient ischemic attack, and one patient who developed heparin-induced thrombocytopenia. No events were noted among patients continuing warfarin (P = .056). Conclusions: While the results were not statistically significant, there was a trend toward reduced complications in patients randomized to warfarin continuation. This strategy should be considered in patients undergoing PPM or ICD implantation.

KW - Anticoagulation

KW - Bleeding

KW - Heparin

KW - ICD

KW - Pacemaker

KW - Stroke

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=79953239765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953239765&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2010.12.016

DO - 10.1016/j.hrthm.2010.12.016

M3 - Article

VL - 8

SP - 536

EP - 540

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 4

ER -